At this time, clinical trials are still ongoing for IFN-γ as a treatment for Her-2 positive BC, as well as ovarian, fallopian tube, and primary peritoneal cancer, and soft tissue sarcoma [75]. The gene discussed is IFNG; the disease is soft tissue sarcoma.